BRIEF-Neurobo Pharmaceuticals Strategic Realignment Ahead Of Important Clinical Milestones With Name Change To Metavia

Reuters11-18

Nov 18 (Reuters) - Neurobo Pharmaceuticals Inc NRBO.O:

NEUROBO PHARMACEUTICALS INC: STRATEGIC REALIGNMENT AHEAD OF IMPORTANT CLINICAL MILESTONES WITH NAME CHANGE TO METAVIA
NEUROBO PHARMACEUTICALS INC: COMMON STOCK WILL BEGIN TRADING ON NASDAQ UNDER "MTVA," WHICH IS EXPECTED TO BE OPERATIVE AS OF NOVEMBER 29

Source text: ID:nPn6xp64za

Further company coverage: NRBO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484273576?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484273576","market":"us","top_or_hot":-1,"title":"BRIEF-Neurobo Pharmaceuticals Strategic Realignment Ahead Of Important Clinical Milestones With Name Change To Metavia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Neurobo Pharmaceuticals Strategic Realignment Ahead Of Important Clinical Milestones With Name Change To Metavia</title></head><body><p><span>Nov 18 (Reuters)</span><span> - </span>Neurobo Pharmaceuticals Inc <span>NRBO.O</span>:</p><ul><li><p>NEUROBO PHARMACEUTICALS INC: STRATEGIC REALIGNMENT AHEAD OF IMPORTANT CLINICAL MILESTONES WITH NAME CHANGE TO METAVIA</p></li><li><p>NEUROBO PHARMACEUTICALS INC: COMMON STOCK WILL BEGIN TRADING ON NASDAQ UNDER \"MTVA,\" WHICH IS EXPECTED TO BE OPERATIVE AS OF NOVEMBER 29</p></li></ul><p>Source text: <span>ID:nPn6xp64za</span></p><p>Further company coverage: <span>NRBO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Neurobo Pharmaceuticals Strategic Realignment Ahead Of Important Clinical Milestones With Name Change To Metavia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Neurobo Pharmaceuticals Strategic Realignment Ahead Of Important Clinical Milestones With Name Change To Metavia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-18 21:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MO02R:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Neurobo Pharmaceuticals Strategic Realignment Ahead Of Important Clinical Milestones With Name Change To MetaviaNov 18 (Reuters) - Neurobo Pharmaceuticals Inc NRBO.O:NEUROBO PHARMACEUTICALS INC:...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MO02R:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MO02R:1","article_id":"2484273576","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484273576","pubTimestamp":1731935979,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Neurobo Pharmaceuticals Strategic Realignment Ahead Of Important Clinical Milestones With Name Change To MetaviaNov 18 (Reuters) - Neurobo Pharmaceuticals Inc NRBO.O:NEUROBO PHARMACEUTICALS INC:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NRBO":"NeuroBo Pharmaceuticals, Inc."},"translate_title":"简介-Neurobo Pharmaceuticals在重要临床里程碑之前进行战略调整，更名为Metavia","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRBO":0.9},"content_text":"BRIEF-Neurobo Pharmaceuticals Strategic Realignment Ahead Of Important Clinical Milestones With Name Change To MetaviaNov 18 (Reuters) - Neurobo Pharmaceuticals Inc NRBO.O:NEUROBO PHARMACEUTICALS INC: STRATEGIC REALIGNMENT AHEAD OF IMPORTANT CLINICAL MILESTONES WITH NAME CHANGE TO METAVIANEUROBO PHARMACEUTICALS INC: COMMON STOCK WILL BEGIN TRADING ON NASDAQ UNDER \"MTVA,\" WHICH IS EXPECTED TO BE OPERATIVE AS OF NOVEMBER 29Source text: ID:nPn6xp64zaFurther company coverage: NRBO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484273576"}